223 related articles for article (PubMed ID: 27627731)
21. [The SPRINT Research. A Randomized Trial of Intensive versus Standard Blood-Pressure Control].
Widimský J
Vnitr Lek; 2016 Jan; 62(1):44-7. PubMed ID: 26967236
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.
CDC Diabetes Cost-effectiveness Group
JAMA; 2002 May; 287(19):2542-51. PubMed ID: 12020335
[TBL] [Abstract][Full Text] [Related]
23. Cost-Effectiveness Analysis of a Pharmacist-Led Medication Therapy Management Program: Hypertension Management.
Schultz BG; Tilton J; Jun J; Scott-Horton T; Quach D; Touchette DR
Value Health; 2021 Apr; 24(4):522-529. PubMed ID: 33840430
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis.
Howard K; White S; Salkeld G; McDonald S; Craig JC; Chadban S; Cass A
Value Health; 2010; 13(2):196-208. PubMed ID: 19878493
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of a Multicomponent Intervention for Hypertension Control in Low-Income Settings in Argentina.
Zhang Y; Yin L; Mills K; Chen J; He J; Palacios A; Riviere AP; Irazola V; Augustovski F; Shi L
JAMA Netw Open; 2021 Sep; 4(9):e2122559. PubMed ID: 34519769
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of Optimal Diastolic Blood Pressure Range Among Adults With Treated Systolic Blood Pressure Less Than 130 mm Hg.
Li J; Somers VK; Gao X; Chen Z; Ju J; Lin Q; Mohamed EA; Karim S; Xu H; Zhang L
JAMA Netw Open; 2021 Feb; 4(2):e2037554. PubMed ID: 33595663
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness analysis of different systolic blood pressure targets for people with a history of stroke or transient ischaemic attack: Economic analysis of the PAST-BP study.
Penaloza-Ramos MC; Jowett S; Barton P; Roalfe A; Fletcher K; Taylor CJ; Hobbs FR; McManus RJ; Mant J
Eur J Prev Cardiol; 2016 Oct; 23(15):1590-8. PubMed ID: 27226338
[TBL] [Abstract][Full Text] [Related]
28. Final Report of a Trial of Intensive versus Standard Blood-Pressure Control.
; Lewis CE; Fine LJ; Beddhu S; Cheung AK; Cushman WC; Cutler JA; Evans GW; Johnson KC; Kitzman DW; Oparil S; Rahman M; Reboussin DM; Rocco MV; Sink KM; Snyder JK; Whelton PK; Williamson JD; Wright JT; Ambrosius WT
N Engl J Med; 2021 May; 384(20):1921-1930. PubMed ID: 34010531
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness analysis of intensive hypertension control in China.
Xie X; He T; Kang J; Siscovick DS; Li Y; Pagán JA
Prev Med; 2018 Jun; 111():110-114. PubMed ID: 29525577
[TBL] [Abstract][Full Text] [Related]
30. Dynamic treatment selection and modification for personalised blood pressure therapy using a Markov decision process model: a cost-effectiveness analysis.
Choi SE; Brandeau ML; Basu S
BMJ Open; 2017 Nov; 7(11):e018374. PubMed ID: 29146652
[TBL] [Abstract][Full Text] [Related]
31. Comparative Cost-effectiveness of the Baerveldt Implant, Trabeculectomy With Mitomycin, and Medical Treatment.
Kaplan RI; De Moraes CG; Cioffi GA; Al-Aswad LA; Blumberg DM
JAMA Ophthalmol; 2015 May; 133(5):560-7. PubMed ID: 25741886
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of the lower treatment goal (of JNC VI) for diabetic hypertensive patients. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
Elliott WJ; Weir DR; Black HR
Arch Intern Med; 2000 May; 160(9):1277-83. PubMed ID: 10809030
[TBL] [Abstract][Full Text] [Related]
33. The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: a Markov decision analysis.
Montgomery AA; Fahey T; Ben-Shlomo Y; Harding J
J Hypertens; 2003 Sep; 21(9):1753-9. PubMed ID: 12923409
[TBL] [Abstract][Full Text] [Related]
34. Cost-Effectiveness of Renal Denervation Therapy for Treatment-Resistant Hypertension: A Best Case Scenario.
Chowdhury EK; Reid CM; Zomer E; Kelly DJ; Liew D
Am J Hypertens; 2018 Sep; 31(10):1156-1163. PubMed ID: 30010694
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events.
Sehested TSG; Bjerre J; Ku S; Chang A; Jahansouz A; Owens DK; Hlatky MA; Goldhaber-Fiebert JD
JAMA Cardiol; 2019 Feb; 4(2):128-135. PubMed ID: 30649147
[TBL] [Abstract][Full Text] [Related]
36. Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Hypertension: SPRINT (Systolic Blood Pressure Intervention Trial).
Soliman EZ; Ambrosius WT; Cushman WC; Zhang ZM; Bates JT; Neyra JA; Carson TY; Tamariz L; Ghazi L; Cho ME; Shapiro BP; He J; Fine LJ; Lewis CE;
Circulation; 2017 Aug; 136(5):440-450. PubMed ID: 28512184
[TBL] [Abstract][Full Text] [Related]
37. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
[TBL] [Abstract][Full Text] [Related]
38. Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe--the HEALTH model.
Schwander B; Gradl B; Zöllner Y; Lindgren P; Diener HC; Lüders S; Schrader J; Villar FA; Greiner W; Jönsson B
Value Health; 2009 Sep; 12(6):857-71. PubMed ID: 19508663
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of Hypertension Management Strategies in SPRINT-Eligible US Adults: A Simulation Study.
Zhang F; Bryant KB; Moran AE; Zhang Y; Cohen JB; Bress AP; Sheppard JP; King JB; Derington CG; Weintraub WS; Kronish IM; Shea S; Bellows BK
J Am Heart Assoc; 2024 Jan; 13(2):e032370. PubMed ID: 38214272
[TBL] [Abstract][Full Text] [Related]
40. Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension.
Jönsson B; Hansson L; Stålhammar NO
J Intern Med; 2003 Apr; 253(4):472-80. PubMed ID: 12653877
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
